Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016;36(5):569-72.
doi: 10.3747/pdi.2015.00010.

Effect of balance Solution on the Peritoneal Membrane in Automated Peritoneal Dialysis

Tatiana De Los Ríos  1 , Juan Pérez-Martínez  2 , Jose Portoles  3 , Monika Lichodziejewska-Niemierko  4 , Maite Rivera  5 , Michał Nowicki  6 , Andrzej Książek  6 , Ana María Tato  7 , Christine Bohnhorst  8 , Mariano Feriani  9
Affiliations
Clinical Trial

Effect of balance Solution on the Peritoneal Membrane in Automated Peritoneal Dialysis

Tatiana De Los Ríos et al. Perit Dial Int. 2016.

Abstract

Interference of conventional peritoneal dialysis fluids (cPDFs) with peritoneal membrane cell functions may be attributed to the dialysis fluid's low pH, high glucose concentration, and/or the presence of glucose degradation products (GDPs), the last of which leads to higher levels of advanced glycation end-products (AGEs). It has been suggested that the peritoneal membrane might be better preserved by using biocompatible solutions, including cancer antigetn 125 (CA125). This prospective, open-label, multicentre, randomized, controlled, cross-over phase IV study compared the in vivo biocompatibility of a neutral-pH, low-GDP peritoneal dialysis (PD) solution (balance) with a cPDF in automated PD (APD) patients. Our study revealed a significantly increased appearance rate and concentration of CA125 in the peritoneal effluent of APD patients treated with the neutral-pH, low-GDP solution balance versus a conventional PD solution.

Keywords: Biocompatibility; cancer antigen 125; pH neutral; peritoneal dialysis fluids; residual renal function; ultrafiltration.

PubMed Disclaimer

References

    1. Schmitt CP, von HD, Rieger S, Arbeiter K, Bonzel KE, Fischbach M, et al. Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content. Nephrol Dial Transplant 2007; 22:2038–44. - PubMed
    1. Wieslander A, Linden T, Kjellstrand P. Glucose degradation products in peritoneal dialysis fluids: how they can be avoided. Perit Dial Int 2001; 21(Suppl 3):S119–24. - PubMed
    1. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al. The Euro-balance trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66:408–18. - PubMed
    1. Rippe B, Simonsen O, Heimburger O, Christensson A, Haraldsson B, Stelin G, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59:348–57. - PubMed
    1. Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranaeus A, et al. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59:1529–38. - PubMed

Publication types

MeSH terms